Search clinical trials for: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Total 857 results

Mayo Clinic
National Cancer Institute (NCI)

Completed

TAS-102 in Treating Advanced Biliary Tract Cancers

Cholangiocarcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon... and other conditions

United States
Roswell Park Cancer Institute
Pfizer

Recruiting

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Advanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditions

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Recurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal Carcinoma

United States
Mayo Clinic

Completed

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditions

United States
Mayo Clinic
National Comprehensive Cancer Network

Completed

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Refractory Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Taiho Pharmaceutical Co., Ltd.

Recruiting

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Unresectable Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Withdrawn

A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer (TACTIC)

Metastatic Triple Negative Breast Cancer

Canada
M.D. Anderson Cancer Center
Taiho

Recruiting

TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal Cancer

United States
Fudan University

Recruiting

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Metastatic Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC (TOBACO)

Advanced Colorectal Cancer | First-line Treatment

China
Baylor Research Institute
Taiho Oncology, Inc.

Recruiting

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (TAS-102 NEC)

High-grade Extra Pulmonary Neuroendocrine Cancer

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)

Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Colorectal Cancer

China
Hellenic Study Group of Psychoneuroimmunology in...
Servier

Completed

A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece (RETRO-TAS)

Metastatic Colorectal Cancer

Greece
National University Hospital, Singapore

Recruiting

Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA)

Breast Cancer

Singapore
Emory University
Ipsen; Taiho Oncology, Inc.

Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Gastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditions

United States
Symphogen A/S

Withdrawn

Sym004 Versus TAS-102 in Patients With mCRC

Carcinoma | Metastatic Colorectal Cancer | Colorectal Cancer Metastatic
Providence Health & Services
Taiho Oncology

Completed

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (SHORT)

Rectal Cancer

United States
Sun Yat-sen University

Not yet recruiting

Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy (TASLARC)

Rectal Cancer

China
Takeda

Completed

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer (APOLLON)

Colorectal Cancer

Japan
University of California, Irvine

Active, not recruiting

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Colorectal Cancer | Metastatic Cancer | Colorectal Carcinoma | CRC

United States
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
AHS Cancer Control Alberta

Not yet recruiting

A Phase II Trial of iTTo in Advanced Gastric and GEJ Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Carcinoma

Canada
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). (PRECONNECT)

Metastatic Colorectal Cancer

Turkey, Poland, Brazil, France, Ireland, Italy, Portugal, Romania, Ukraine, Bulgaria, Australia, Belgium, Croatia, Panama, Slovakia, Slovenia
Henan Cancer Hospital

Recruiting

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)

Colorectal Neoplasms

Italy, Canada, Korea, Republic of, Sweden, United States, Argentina, Australia, Austria, Belgium, Chile, China, Czechia, France, Germany, Japan, Netherlands, Poland, Puerto Rico, Singapore, Spain, Switzerland, Taiwan
Servier Deutschland GmbH
iOMEDICO AG

Completed

Trifluridin/tipirACil in meTastatIc Colorectal Cancer (TACTIC)

Metastatic Colorectal Cancer

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

Metastatic Colorectal Cancer

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8

United States
Centre Georges Francois Leclerc

Recruiting

Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN)

Metastatic Colorectal Cancer

France
Holy Stone Healthcare Co., Ltd

Not yet recruiting

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Adenocarcinoma

United States, Japan, Puerto Rico, Taiwan, Spain, Australia, France, Israel, Korea, Republic of, Poland
University of California, Irvine
Taiho Pharmaceutical Co., Ltd.

Completed

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | GastroEsophageal Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Metastatic Colorectal Cancer

China
UNICANCER

Active, not recruiting

Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT)

Metastatic Colorectal Cancer

France, Belgium
Taiho Oncology, Inc.

Completed

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Advanced Solid Tumors

United States
Hunan Cancer Hospital

Completed

Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Astex Pharmaceuticals, Inc.; Van Andel Research Institute

Completed

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Previously Treated Metastatic Colorectal Cancer

United States, Netherlands
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Colorectal Neoplasms

United States, Argentina, Australia, Canada, China, Denmark, Germany, Israel, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
GERCOR - Multidisciplinary Oncology Cooperative...

Active, not recruiting

LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy (LONGBOARD)

Metastatic Colorectal Cancer

France
Bayer

Active, not recruiting

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions (STAR-T)

Metastatic Colorectal Cancer (mCRC)

United States

Search clinical trials for: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations